• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2023 Dec 14;23(1):877.
doi: 10.1186/s12879-023-08898-2. New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study

Fhabián S Carrión-Nessi[SUP] 1 2 3 [/SUP], Luis C Ascanio[SUP] 4 [/SUP], Andreína G Pineda-Arapé[SUP] 2 [/SUP], Óscar D Omaña-Ávila[SUP] 1 2 3 [/SUP], Daniela L Mendoza-Millán[SUP] 1 2 3 [/SUP], Sinibaldo R Romero[SUP] 1 5 [/SUP], Abranny B Almao-Rivero[SUP] 2 [/SUP], Natasha A Camejo-Ávila[SUP] 1 2 [/SUP], Karim J Gebran-Chedid[SUP] 1 [/SUP], Carlis M Rodriguez-Saavedra[SUP] 1 [/SUP], Diana C Freitas-De Nobrega[SUP] 1 2 [/SUP], Sergio A Castañeda[SUP] 6 [/SUP], José L Forero-Peña[SUP] 1 [/SUP], Lourdes A Delgado-Noguera[SUP] 2 [/SUP], Lucianny K Meneses-Ramírez[SUP] 7 [/SUP], Juan C Cotuá[SUP] 1 [/SUP], Alfonso J Rodriguez-Morales[SUP] 8 9 [/SUP], David A Forero-Peña[SUP] 10 11 12 13 [/SUP], Alberto E Paniz-Mondolfi[SUP] 14 15 [/SUP]



Affiliations
Abstract

Background: Persistent headache is a frequent symptom after coronavirus disease 2019 (COVID-19) and there is currently limited knowledge about its clinical spectrum and predisposing factors. A subset of patients may be experiencing new daily persistent headache (NDPH) after COVID-19, which is among the most treatment-refractory primary headache syndromes.
Methods: We conducted a cross-sectional study in Latin America to characterize individuals with persistent headache after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify factors associated with NDPH. Participants over 18 years old who tested positive for SARS-CoV-2 infection and reported persistent headache among their symptoms completed an online survey that included demographics, past medical history, persistent headache clinical characteristics, and COVID-19 vaccination status. Based on participants' responses, NDPH diagnostic criteria were used to group participants into NDPH and non-NDPH groups. Participant data was summarized by descriptive statistics. Student's t and Mann-Whitney U tests were used according to the distribution of quantitative variables. For categorical variables, Pearson's chi-square and Fisher's exact tests were used according to the size of expected frequencies. Binomial logistic regression using the backward stepwise selection method was performed to identify factors associated with NDPH.
Results: Four hundred and twenty-one participants from 11 Latin American countries met the inclusion criteria. One in four participants met the NDPH diagnostic criteria. The mean age was 40 years, with most participants being female (82%). Over 90% of the participants reported having had mild/moderate COVID-19. Most participants had a history of headache before developing COVID-19 (58%), mainly migraine type (32%). The most predominant clinical characteristics in the NDPH group were occipital location, severe/unbearable intensity, burning character, and radiating pain (p < 0.05). A higher proportion of anxiety symptoms, sleep problems, myalgia, mental fog, paresthesia, nausea, sweating of the face or forehead, and ageusia or hypogeusia as concomitant symptoms were reported in participants with NDPH (p < 0.05). Palpebral edema as a concomitant symptom during the acute phase of COVID-19, occipital location, and burning character of the headache were risk factors associated with NDPH.
Conclusion: This is the first study in Latin America that explored the clinical spectrum of NDPH after SARS-CoV-2 infection and its associated factors. Clinical evaluation of COVID-19 patients presenting with persistent headache should take into consideration NDPH.

Keywords: COVID-19; Cross-sectional survey; Latin America; Long COVID; NDPH; New daily persistent headache; SARS-CoV-2.

 
Back
Top Bottom